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OBJECTIVES: The need and price for cancer drugs will increase while budgets are becoming more 
constrained. Policy makers need to make hard choices about which drugs are worthwhile. Inclusion of 
societal preferences in resource allocation is emphasized by academic research and policy makers. This 
study qualitatively assesses societal preferences for market access of cancer drugs. METHODS: Focus 
group discussions (FGD) with members of the general population in Flanders (Belgium) were organized. 
Participants were recruited through flyers distributed in the University Hospitals Leuven and social 
media. First, the topic of budgetary constraints and resource allocation was introduced. Next, 
introductory statements based on ethical principles were discussed. Hypothetical scenarios were set 
up to ask people about characteristics of a patient, disease and drug that they would use to prioritize 
if there is only money to use/treat one of them. FGD were led by one researcher, video and audio 
recorded, verbatim transcribed and analyzed using thematic framework analysis. FGD were repeated 
until data saturation. Participants received a compensation of €20. RESULTS: Three FGD with six 
participants were conducted in February 2015. The median age of participants was 43 years (22-65, 
N=18). When participants are asked to define criteria they would use to prioritize patients, they 
mention age and life style of a patient and severity of the disease. They prefer to treat the largest 
patient group with the best prognosis. Drugs would be prioritized by participants based on the effect 
on quality of life, side effects and treatment duration. CONCLUSIONS: Participants would like to 
maximize the benefits within a restricted budget, but conflicts between criteria such as prognosis and 
severity of disease and between effect on quality of life and side effects crop up. Further research will 
quantify the relative importance and the trade-offs between criteria that society is willing to make 
through a discrete choice experiment.  
  
